On November 12, ADVI Health’s head of federal and state policy, Lindsay Bealor Greenleaf, was featured in MedCity News’ article discussing what the prescription drug world will likely look like under the incoming Trump administration when it comes to research and development, drug pricing, and PBM reform.

In the article, What Might the Future of Prescription Drugs Look Like Under Trump?, Lindsay shares her thoughts on what will happen next with the Inflation Reduction Act (IRA). Lindsay talked about how if Republicans do take control of both chambers of Congress come January, they are likely to introduce a “big reconciliation package next year that may very well include changes to the IRA government negotiation policy.”

Read more in MedCity News.